Loading...

Buy Full Version
"Head & Neck Cancer Drugs Market"

Let us help you !

Invalid Email.

Please Select Country.

Invalid contact no.

Special Symbols Not Allowed.

Invalid Security Code.

Thank You For Your Interest.

We've Successfully Got Your Message,

Our Executive will get back to you Shortly.

Head & Neck Cancer Drugs Market by Drug Class (Chemotherapy, Immunotherapy, and Targeted Therapy) and Sales Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Stores): Global Opportunity Analysis and Industry Forecast, 2018 - 2025

LI_195174
Pages: 201
Feb 2019 | 2473 Views
 
Author(s) : Onkar Sumant & Sayali Shinde
Tables: 88
Charts: 37
 

Head & Neck Cancer Drugs Market Overview:

The global head & neck cancer drugs market was valued at $1,295 million in 2017, and is projected to reach $2,281 million by 2025, registering a CAGR of 7.3% from 2018 to 2025.

Head & neck cancers include a number of different malignant tumors that develop in or around the throat, larynx, nose, sinuses, lips, salivary glands, and mouth. There are different types of drugs used alone or in combination for treatment of head & neck cancer. Although traditional chemotherapeutic drugs preferably used in combination of radiation therapy, targeted immune therapies are emerging as a standard treatment option for advanced-stage head & neck cancers.

Increase in prevalence of head & neck cancer across geographies, rise in demand for combination therapy for management of head & neck cancer, and growth in number of R&D activities to develop ideal therapeutic drive the growth of the global head & neck cancer drugs market. Furthermore, technological advancements in screening procedure for cancer and strong presence of pipeline drugs such as Ipilimumab, Atezolizumab, Avelumab, Durvalumab, Erlotinib, Afatinib, Bevacizumab, and others are expected to drive the market growth. In addition, rise in number of risk factors such as growth in number of cigarette smoking, alcohol & tobacco consumption is further anticipated to fuel the growth of the global head & neck cancer drugs market.

Head & Neck Cancer Drugs Market Segmentation

The global head & neck cancer drugs market is segmented based on drug class, sales channel, and region. Based on drug class, the market is classified into chemotherapy, immunotherapy, and targeted therapy. According to the sales channel, it is categorized into hospital pharmacies, drug stores & retail pharmacies, and online stores. Based on region, the head and neck cancer drugs market size is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, and rest of LAMEA).

Get more information on this report: Request Sample Pages

Segment review

Based on drug class, the head & neck cancer drugs market is classified into chemotherapy, immunotherapy, and targeted therapy. The chemotherapy segment occupied the largest head & neck cancer drugs market share, this is attributed to increase in usage of chemotherapeutic drugs during radiation therapy and rise in benefits of combination therapy. Currently, drugs such as bleomycin, cetuximab, docetaxel, paclitaxel, capecitabine, hydroxyurea, methotrexate, docetaxel, 5-fluorouracil, and methotrexate are approved for treatment of head & neck cancer. Therefore, surge in prevalence of head & neck cancer and rise in adoption of chemotherapeutics for treatment of head & neck cancer along with other therapeutics drive the market growth of this segment. However, chemotherapeutic agents are cytotoxic that harm malignant as well as healthy cells in cancer patients, which is a major factor that restrains the growth of the market. Moreover, the demand for immunotherapy is expected to increase during the forecast period due to rise in adoption of targeted immune therapeutics drugs and strong presence of pipeline drugs. Drugs such as Pembrolizumab (Keytruda) by Merck & Company and Nivolumab (Opdivo), developed by Bristol-Myers Squibb are approved by the U.S. food and drug administration (FDA) for the treatment of recurrent or metastatic head & neck squamous cell carcinoma (HNSCC), which has not been stopped by platinum-based chemotherapy. Expected launch of pipeline drugs such as Ipilimumab, Atezolizumab, Avelumab, and Durvalumab is expected to further drive the market growth.

Get more information on this report: Request Sample Pages

Based on sales channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online stores. The online providers segment is expected to experience fastest growth over the forecast period due to rise in preference for online purchasing of drugs over the traditional methods, increase in number of internet users, and growth in awareness about online pharmacy. However, drug stores & retail pharmacies segment dominated the market in 2017 due to its higher presence.

Get more information on this report: Request Sample Pages

Snapshot of Asia-Pacific head & neck cancer drugs market

Asia-Pacific presents lucrative growth opportunities for the key players operating in the head & neck cancer drugs market owing to large population base, surge in incidence of head & neck cancer, and increase in demand for head & neck cancer combination therapeutics. Risk factors such as growth in alcohol consumption, increase in cigarette smoking, and higher usage of tobacco are further expected to fuel the market growth. Betel quid chewing is the most common form of tobacco chewing in the Asia-Pacific region. Furthermore, increase in awareness toward treatment & early screening of the disease and rise in healthcare expenditure fuel the growth of the market in this region.

Get more information on this report: Request Sample Pages

The key players profiled in this report include AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company (ARMO Biosciences), Fortress Biotech, Inc. (Checkpoint Therapeutics, Inc.), F. Hoffmann-La Roche Ltd. (Genentech, Inc.), Immutep Limited, Merck & Co., Inc., Merck KGaA (EMD Serono, Inc.), Novartis AG, and Pfizer Inc.

Key Benefits for Head & Neck Cancer Drugs Market:

  • The study provides an in-depth analysis of the market along with the current head & neck cancer drugs market trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Head & neck cancer drugs market forecast is studied from 2018 to 2025.
  • A comprehensive analysis of all the geographical regions is provided to determine the prevailing opportunities.
  • Head & neck cancer drugs market size and estimations are based on a comprehensive analysis of key developments in the head and neck cancer drugs industry.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

Head & Neck Cancer Drugs Key Market Segments:

By Drug Class

  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy

By Sales Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Stores

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1:    INTRODUCTION

1.1.    Report description
1.2.    Key benefits for stakeholders
1.3.    Key market segments

1.3.1.    List of key players profiled in the report

1.4.    Research methodology

1.4.1.    Secondary research
1.4.2.    Primary research
1.4.3.    Analyst tools and models

CHAPTER 2:    EXECUTIVE SUMMARY

2.1.    Key findings of the study

2.1.1.    CXO perspective

CHAPTER 3:    MARKET OVERVIEW

3.1.    Market definition and scope
3.2.    Key findings

3.2.1.    Top investment pockets
3.2.2.    Top player positioning

3.3.    MARKET DYNAMICS

3.3.1.    Drivers

3.3.1.1.    Surge in incidence of head and neck cancer worldwide
3.3.1.2.    Surge in global geriatric population
3.3.1.3.    Increase in consumption of tobacco and alcohol

3.3.2.    Restraints

3.3.2.1.    Adverse effects associated with the use of head and neck cancer drugs

3.3.3.    Opportunities

3.3.3.1.    Untapped emerging economies
3.3.3.2.    Increase in number of pipeline drugs

3.3.4.    Impact Analyses

CHAPTER 4:    HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS

4.1.    Overview

4.1.1.    Market size and forecast

4.2.    Chemotherapy

4.2.1.    Key market trends, growth factors, and opportunities
4.2.2.    Market size and forecast
4.2.3.    Market analysis, by country

4.3.    Immunotherapy

4.3.1.    Key market trends, growth factors, and opportunities
4.3.2.    Market size and forecast
4.3.3.    Market analysis, by country

4.4.    Targeted therapy

4.4.1.    Key market trends, growth factors, and opportunities
4.4.2.    Market size and forecast
4.4.3.    Market analysis, by country

CHAPTER 5:    HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL

5.1.    Overview

5.1.1.    Market size and forecast

5.2.    Hospital pharmacy

5.2.1.    Market size and forecast, by region
5.2.2.    Market analysis, by country

5.3.    Online providers

5.3.1.    Market size and forecast, by region
5.3.2.    Market analysis, by country

5.4.    Drug stores & retail pharmacies

5.4.1.    Market size and forecast, by region
5.4.2.    Market analysis, by country

CHAPTER 6:    HEAD & NECK CANCER DRUGS MARKET, BY REGION

6.1.    Overview

6.1.1.    Market size and forecast

6.2.    North America

6.2.1.    Key market trends, growth factors, and opportunities
6.2.2.    North America market size and forecast, by country

6.2.2.1.    U.S.

6.2.2.1.1.    U.S. head & neck cancer drugs market, by drug class
6.2.2.1.2.    U.S. head & neck cancer drugs market, by sales channel

6.2.2.2.    Canada

6.2.2.2.1.    Canada head & neck cancer drugs market, by drug class
6.2.2.2.2.    Canada head & neck cancer drugs market, by sales channel

6.2.2.3.    Mexico

6.2.2.3.1.    Mexico head & neck cancer drugs market, by drug class
6.2.2.3.2.    Mexico head & neck cancer drugs market, by sales channel

6.2.3.    North America market size and forecast, by drug class
6.2.4.    North America market size and forecast, by sales channel

6.3.    Europe

6.3.1.    Key market trends, growth factors, and opportunities
6.3.2.    Europe market size and forecast, by country

6.3.2.1.    Germany

6.3.2.1.1.    Germany head & neck cancer drugs market, by drug class
6.3.2.1.2.    Germany head & neck cancer drugs market, by sales channel

6.3.2.2.    France

6.3.2.2.1.    France head & neck cancer drugs market, by drug class
6.3.2.2.2.    France head & neck cancer drugs market, by sales channel

6.3.2.3.    UK

6.3.2.3.1.    UK head & neck cancer drugs market, by drug class
6.3.2.3.2.    UK head & neck cancer drugs market, by sales channel

6.3.2.4.    Italy

6.3.2.4.1.    Italy head & neck cancer drugs market, by drug class
6.3.2.4.2.    Italy head & neck cancer drugs market, by sales channel

6.3.2.5.    Spain

6.3.2.5.1.    Spain head & neck cancer drugs market, by drug class
6.3.2.5.2.    Spain head & neck cancer drugs market, by sales channel

6.3.2.6.    Rest of Europe

6.3.2.6.1.    Rest of Europe head & neck cancer drugs market, by drug class
6.3.2.6.2.    Rest of Europe head & neck cancer drugs market, by sales channel

6.3.3.    Europe market size and forecast, by drug class
6.3.4.    Europe market size and forecast, by sales channel

6.4.    Asia-Pacific

6.4.1.    Key market trends, growth factors, and opportunities
6.4.2.    Asia-Pacific market size and forecast, by country

6.4.2.1.    Japan

6.4.2.1.1.    Japan head & neck cancer drugs market, by drug class
6.4.2.1.2.    Japan head & neck cancer drugs market, by sales channel

6.4.2.2.    China

6.4.2.2.1.    China head & neck cancer drugs market, by drug class
6.4.2.2.2.    China head & neck cancer drugs market, by sales channel

6.4.2.3.    Australia

6.4.2.3.1.    Australia head & neck cancer drugs market, by drug class
6.4.2.3.2.    Australia head & neck cancer drugs market, by sales channel

6.4.2.4.    India

6.4.2.4.1.    India head & neck cancer drugs market, by drug class
6.4.2.4.2.    India head & neck cancer drugs market, by sales channel

6.4.2.5.    South Korea

6.4.2.5.1.    South Korea head & neck cancer drugs market, by drug class
6.4.2.5.2.    South Korea head & neck cancer drugs market, by sales channel

6.4.2.6.    Rest of Asia-Pacific

6.4.2.6.1.    Rest of Asia-Pacific head & neck cancer drugs market, by drug class
6.4.2.6.2.    Rest of Asia-Pacific head & neck cancer drugs market, by sales channel

6.4.3.    Asia-Pacific market size and forecast, by type
6.4.4.    Asia-Pacific market size and forecast, by sales channel

6.5.    LAMEA

6.5.1.    Key market trends, growth factors, and opportunities
6.5.2.    LAMEA market size and forecast, by country

6.5.2.1.    Brazil

6.5.2.1.1.    Brazil head & neck cancer drugs market, by drug class
6.5.2.1.2.    Brazil head & neck cancer drugs market, by sales channel

6.5.2.2.    Saudi Arabia

6.5.2.2.1.    Saudi Arabia head & neck cancer drugs market, by drug class
6.5.2.2.2.    Saudi Arabia head & neck cancer drugs market, by sales channel

6.5.2.3.    South Africa

6.5.2.3.1.    South Africa head & neck cancer drugs market, by drug class
6.5.2.3.2.    South Africa head & neck cancer drugs market, by sales channel

6.5.2.4.    Rest of LAMEA

6.5.2.4.1.    Rest of LAMEA head & neck cancer drugs market, by drug class
6.5.2.4.2.    Rest of LAMEA head & neck cancer drugs market, by sales channel

6.5.3.    LAMEA market size and forecast, by type
6.5.4.    LAMEA market size and forecast, by sales channel

CHAPTER 7:    COMPANY PROFILES

7.1.    AstraZeneca Plc.

7.1.1.    Company overview
7.1.2.    Company snapshot
7.1.3.    Operating business segments
7.1.4.    Product Portfolio
7.1.5.    Business performance

7.2.    Bristol-Myers Squibb Company

7.2.1.    Company overview
7.2.2.    Company snapshot
7.2.3.    Operating business segments
7.2.4.    Product portfolio
7.2.5.    Business performance
7.2.6.    Key strategic moves and developments

7.3.    Eli Lilly and Company

7.3.1.    Company overview
7.3.2.    Company snapshot
7.3.3.    Operating business segments
7.3.4.    Product Portfolio
7.3.5.    Business performance

7.4.    F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)

7.4.1.    Company overview
7.4.2.    Company snapshot
7.4.3.    Operating business segments
7.4.4.    Product portfolio
7.4.5.    Business performance

7.5.    Fresenius Medical Care AG & Co. KGaA

7.5.1.    Company overview
7.5.2.    Company snapshot
7.5.3.    Operating business segments
7.5.4.    Product Portfolio
7.5.5.    Business performance

7.6.    Merck & Co., Inc.

7.6.1.    Company overview
7.6.2.    Company snapshot
7.6.3.    Operating business segments
7.6.4.    Product Portfolio
7.6.5.    Business performance
7.6.6.    Key strategic moves and developments

7.7.    Pfizer Inc.

7.7.1.    Company overview
7.7.2.    Company snapshot
7.7.3.    Operating business segments
7.7.4.    Product Portfolio
7.7.5.    Business performance

7.8.    Sanofi

7.8.1.    Company overview
7.8.2.    Company snapshot
7.8.3.    Operating business segments
7.8.4.    Product Portfolio
7.8.5.    Business performance
7.8.6.    Key strategic moves and developments

7.9.    Sun Pharmaceutical Industries Ltd.

7.9.1.    Company overview
7.9.2.    Company snapshot
7.9.3.    Operating business segments
7.9.4.    Product Portfolio
7.9.5.    Business performance

7.10.    Teva Pharmaceutical Industries Limited

7.10.1.    Company overview
7.10.2.    Company snapshot
7.10.3.    Operating business segments
7.10.4.    Product Portfolio
7.10.5.    Business performance
7.10.6.Key strategic moves and developments

LIST OF TABLES

TABLE 01.    GLOBAL HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 2017–2025 ($MILLION)
TABLE 02.    CHEMOTHERAPY MARKET FOR HEAD & NECK CANCER, BY REGION, 2017–2025 ($MILLION)
TABLE 03.    IMMUNOTHERAPY MARKET FOR HEAD & NECK CANCER, BY REGION, 2017–2025 ($MILLION)
TABLE 04.    TARGETED THERAPY MARKET FOR HEAD & NECK CANCER, BY REGION, 2017–2025 ($MILLION)
TABLE 05.    GLOBAL HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 2017–2025 ($MILLION)
TABLE 06.    HEAD & NECK CANCER DRUGS MARKET FOR HOSPITAL PHARMACY, BY REGION, 2017–2025 ($MILLION)
TABLE 07.    HEAD & NECK CANCER DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2017–2025 ($MILLION)
TABLE 08.    HEAD & NECK CANCER DRUGS MARKET FOR DRUG STORES & RETAIL PHARMACIES, BY REGION, 2017–2025 ($MILLION)
TABLE 09.    HEAD & NECK CANCER DRUGS MARKET REVENUE, BY REGION, 2017–2025 ($MILLION)
TABLE 10.    NORTH AMERICA HEAD & NECK CANCER DRUGS MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 11.    U.S. HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 2017–2025 ($MILLION)
TABLE 12.    U.S. HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 2017–2025 ($MILLION)
TABLE 13.    CANADA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 2017–2025 ($MILLION)
TABLE 14.    CANADA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 2017–2025 ($MILLION)
TABLE 15.    MEXICO HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 2017–2025 ($MILLION)
TABLE 16.    MEXICO HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 2017–2025 ($MILLION)
TABLE 17.    NORTH AMERICA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 2017–2025 ($MILLION)
TABLE 18.    NORTH AMERICA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 2017–2025 ($MILLION)
TABLE 19.    EUROPE HEAD & NECK CANCER DRUGS MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 20.    GERMANY HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 2017–2025 ($MILLION)
TABLE 21.    GERMANY HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 2017–2025 ($MILLION)
TABLE 22.    FRANCE HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 2017–2025 ($MILLION)
TABLE 23.    FRANCE HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 2017–2025 ($MILLION)
TABLE 24.    UK HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 2017–2025 ($MILLION)
TABLE 25.    UK HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 2017–2025 ($MILLION)
TABLE 26.    ITALY HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 2017–2025 ($MILLION)
TABLE 27.    ITALY HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 2017–2025 ($MILLION)
TABLE 28.    SPAIN HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 2017–2025 ($MILLION)
TABLE 29.    SPAIN HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 2017–2025 ($MILLION)
TABLE 30.    REST OF EUROPE HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 2017–2025 ($MILLION)
TABLE 31.    REST OF EUROPE HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 2017–2025 ($MILLION)
TABLE 32.    EUROPE HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 2017–2025 ($MILLION)
TABLE 33.    EUROPE HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 2017–2025 ($MILLION)
TABLE 34.    ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 35.    JAPAN HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 2017–2025 ($MILLION)
TABLE 36.    JAPAN HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 2017–2025 ($MILLION)
TABLE 37.    CHINA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 2017–2025 ($MILLION)
TABLE 38.    CHINA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 2017–2025 ($MILLION)
TABLE 39.    AUSTRALIA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 2017–2025 ($MILLION)
TABLE 40.    AUSTRALIA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 2017–2025 ($MILLION)
TABLE 41.    INDIA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 2017–2025 ($MILLION)
TABLE 42.    INDIA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 2017–2025 ($MILLION)
TABLE 43.    SOUTH KOREA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 2017–2025 ($MILLION)
TABLE 44.    SOUTH KOREA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 2017–2025 ($MILLION)
TABLE 45.    REST OF ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 2017–2025 ($MILLION)
TABLE 46.    REST OF ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 2017–2025 ($MILLION)
TABLE 47.    ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 2017–2025 ($MILLION)
TABLE 48.    ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 2017–2025 ($MILLION)
TABLE 49.    LAMEA HEAD & NECK CANCER DRUGS MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 50.    BRAZIL HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 2017–2025 ($MILLION)
TABLE 51.    BRAZIL HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 2017–2025 ($MILLION)
TABLE 52.    SAUDI ARABIA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 2017–2025 ($MILLION)
TABLE 53.    SAUDI ARABIA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 2017–2025 ($MILLION)
TABLE 54.    SOUTH AFRICA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 2017–2025 ($MILLION)
TABLE 55.    SOUTH AFRICA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 2017–2025 ($MILLION)
TABLE 56.    REST OF LAMEA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 2017–2025 ($MILLION)
TABLE 57.    REST OF LAMEA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 2017–2025 ($MILLION)
TABLE 58.    LAMEA HEAD & NECK CANCER DRUGS MARKET, BY DRUG CLASS, 2017–2025 ($MILLION)
TABLE 59.    LAMEA HEAD & NECK CANCER DRUGS MARKET, BY SALES CHANNEL, 2017–2025 ($MILLION)
TABLE 60.    ASTRAZENECA: COMPANY SNAPSHOT
TABLE 61.    ASTRAZENECA: OPERATING SEGMENTS
TABLE 62.    ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 63.    BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 64.    BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
TABLE 65.    LILLY: COMPANY SNAPSHOT
TABLE 66.    LILLY: OPERATING SEGMENTS
TABLE 67.    LILLY: PRODUCT PORTFOLIO
TABLE 68.    ROCHE: COMPANY SNAPSHOT
TABLE 69.    ROCHE: OPERATING SEGMENTS
TABLE 70.    ROCHE: PRODUCT PORTFOLIO
TABLE 71.    FRESENIUS MEDICAL CARE: COMPANY SNAPSHOT
TABLE 72.    FRESENIUS MEDICAL CARE: OPERATING SEGMENTS
TABLE 73.    FRESENIUS MEDICAL CARE: PRODUCT PORTFOLIO
TABLE 74.    MERCK: COMPANY SNAPSHOT
TABLE 75.    MERCK: OPERATING SEGMENTS
TABLE 76.    MERCK: PRODUCT PORTFOLIO
TABLE 77.    PFIZER: COMPANY SNAPSHOT
TABLE 78.    PFIZER: OPERATING SEGMENTS
TABLE 79.    PFIZER: PRODUCT PORTFOLIO
TABLE 80.    SANOFI: COMPANY SNAPSHOT
TABLE 81.    SANOFI: OPERATING SEGMENTS
TABLE 82.    SANOFI: PRODUCT PORTFOLIO
TABLE 83.    SUN PHARMA: COMPANY SNAPSHOT
TABLE 84.    SUN PHARMA: OPERATING SEGMENTS
TABLE 85.    SUN PHARMA: PRODUCT PORTFOLIO
TABLE 86.    TEVA: COMPANY SNAPSHOT
TABLE 87.    TEVA: OPERATING SEGMENTS
TABLE 88.    TEVA: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.    HEAD & NECK CANCER DRUGS MARKET SEGMENTATION
FIGURE 02.    TOP INVESTMENT POCKETS IN THE GLOBAL HEAD & NECK CANCER DRUGS MARKET
FIGURE 03.    TOP PLAYER POSITIONING, 2017
FIGURE 04.    WORLD POPULATION AGED 65 AND OVER (%)
FIGURE 05.    IMPACT ANALYSES, HEAD AND NECK CANCER DRUG MARKET
FIGURE 06.    COMPARATIVE COUNTRY ANALYSIS OF CHEMOTHERAPY MARKET FOR HEAD & NECK CANCER, 2017 AND 2025 ($MILLION)
FIGURE 07.    COMPARATIVE COUNTRY ANALYSIS OF IMMUNOTHERAPY MARKET FOR HEAD & NECK CANCER, 2017 AND 2025 ($MILLION)
FIGURE 08.    COMPARATIVE COUNTRY ANALYSIS OF TARGETED THERAPY MARKET FOR HEAD & NECK CANCER, 2017 AND 2025 ($MILLION)
FIGURE 09.    COMPARATIVE COUNTRY ANALYSIS HEAD & NECK CANCER DRUGS MARKET FOR HOSPITAL PHARMACY, 2017 AND 2025 ($MILLION)
FIGURE 10.    COMPARATIVE COUNTRY ANALYSIS HEAD & NECK CANCER DRUGS MARKET FOR ONLINE PROVIDERS, 2017 AND 2025 ($MILLION)
FIGURE 11.    COMPARATIVE COUNTRY ANALYSIS HEAD & NECK CANCER DRUGS MARKET FOR DRUG STORES & RETAIL PHARMACIES, 2017 AND 2025 ($MILLION)
FIGURE 12.    ASTRAZENECA: REVENUE, 2015–2017 ($MILLION)
FIGURE 13.    ASTRAZENECA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 14.    REVENUE, 2015–2017 ($MILLION)
FIGURE 15.    BRISTOL-MYERS SQUIBB: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 16.    REVENUE, 2015–2017 ($MILLION)
FIGURE 17.    LILLY: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 18.    LILLY: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 19.    ROCHE: NET SALES, 2015–2017 ($MILLION)
FIGURE 20.    ROCHE: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 21.    ROCHE: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 22.    FRESENIUS MEDICAL CARE: NET SALES, 2015–2017 ($MILLION)
FIGURE 23.    FRESENIUS MEDICAL CARE: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 24.    MERCK: NET SALES, 2015–2017 ($MILLION)
FIGURE 25.    MERCK: NET SALES BY SEGMENT, 2017 (%)
FIGURE 26.    MERCK: NET SALES BY GEOGRAPHY, 2017 (%)
FIGURE 27.    PFIZER: REVENUE, 2015–2017 ($MILLION)
FIGURE 28.    PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 29.    PFIZER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 30.    SANOFI: NET SALES, 2015–2017 ($MILLION)
FIGURE 31.    SANOFI: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 32.    SANOFI: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 33.    SUN PHARMA: NET SALES, 2015–2017 ($MILLION)
FIGURE 34.    SUN PHARMA: NET SALES BY SEGMENT, 2017 (%)
FIGURE 35.    TEVA: REVENUE, 2015–2017 ($MILLION)
FIGURE 36.    TEVA: REVENUE BY SEGMENT, 2017 (%)
FIGURE 37.    TEVA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

 
 

Head & neck cancer includes the cancers of mouth, nose, throat, larynx, sinuses, or salivary glands. Drugs such as chemotherapy, immune therapy, and targeted therapy are used for treatment of  head & neck cancers. The adoption of head & neck cancer drugs is expected to increase due to rise in the prevalence of head & neck cancer across the world and increase in adoption of combination therapy along with radiation therapy and surgical procedures.

Rise in R&D studies for the development of ideal therapeutics, strong presence of pipeline drugs, and growth in adoption of head & neck cancer drugs are projected to supplement the market growth during the forecast period. Moreover, rise in number of risk factors such as growing cigarette smoking, alcohol & tobacco consumption is further expected to fuel the market growth. However, complications associated with the use of head & neck cancer drugs can hinder the market growth.

North America is expected to remain dominant during the forecast period due to surge in use of head & neck cancer drugs owing to wide presence of advanced therapeutics, higher number of target population. In addition, Asia-Pacific and LAMEA are expected to offer lucrative growth opportunities to the key players during the forecast period due to increase in incidence of head & neck cancer, improvement in healthcare infrastructure with developing economies, and growth in the need for combination therapy.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry

Download Sample

Request Customization

Download Sample

OR

Purchase Full Report of
Head & Neck Cancer Drugs Market

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,370
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 
image image image image image image image image image image image image image image image image image image image
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

FREQUENTLY ASKED
QUESTIONS?

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 
Download Sample